Success-Driven Drug Discovery with OpenBench CEO James Yoder

What if your drug discovery partner only charged you when they found something that actually worked?

In this episode of Data in Biotech, host Ross Katz sits down with James Yoder, Founder & CEO of OpenBench, to explore a bold new model for early-stage drug discovery. One where risk shifts away from biotech partners and results do the talking.

From computational screening and molecular modeling to data flywheels and AI-powered hit scoring, James unpacks how OpenBench is making drug discovery smarter, faster, and more accessible.

Listen now.

Apple
Spotify
‍YouTube